Journal of Industrial Microbiology

, Volume 15, Issue 1, pp 60–65

Korkormicins, novel depsipeptide antitumor antibiotics fromMicromonospora sp C39500: Fermentation, precursor directed biosynthesis and biological activities

Authors

  • K S Lam
    • Bristol-Myers Squibb Pharmaceutical Research Institute
  • D R Gustavson
    • Bristol-Myers Squibb Pharmaceutical Research Institute
  • G A Hesler
    • Bristol-Myers Squibb Pharmaceutical Research Institute
  • T T Dabrah
    • Bristol-Myers Squibb Pharmaceutical Research Institute
  • J A Matson
    • Bristol-Myers Squibb Pharmaceutical Research Institute
  • R L Berry
    • Bristol-Myers Squibb Pharmaceutical Research Institute
  • W C Rose
    • Bristol-Myers Squibb Pharmaceutical Research Institute
  • S Forenza
    • Bristol-Myers Squibb Pharmaceutical Research Institute
Article

DOI: 10.1007/BF01570015

Cite this article as:
Lam, K.S., Gustavson, D.R., Hesler, G.A. et al. Journal of Industrial Microbiology (1995) 15: 60. doi:10.1007/BF01570015

Abstract

Micromonospora sp C39500, isolated in our laboratory from a soil sample, produced a complex of seven novel depsipeptide antitumor antibiotics, designated korkormicins. The major component of the complex, korkormicin A, has a MW of 1452 and a molecular formula of C66H84N16O22. Korkormicin A exhibits potentin vivo antitumor activity against P388 leukemia and M109 lung carcinoma implanted intraperitoneally (ip) in mice, with effective doses of 0.05–0.20 mg kg−1 injection−1, for five or three ip injections, respectively. It is also active against Gram-positive bacteria but inactive against Gram-negative bacteria. The production of korkormicin A was enhanced by 3-fold when 0.1%l-valine was added to the production culture at 48h. A titer of 401.0 μg ml−1 was achieved in the fermenter culture supplemented with 0.1%l-valine.

Keywords

korkormicinsdepsipeptideantitumor antibioticdirected biosynthesis

Copyright information

© Society for Industrial Microbiology 1995